Companies › Organon and
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Immunology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tapinarof Aryl hydrocarbon receptor agonist | AHR | Phase 3 | Plaque Psoriasis; Atopic Dermatitis; Palmoplantar Keratoderma | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05172726 | Tapinarof | Phase 3 | Plaque Psoriasis | Immunology | Oct 2026 |
| NCT07265479 | Tapinarof | Phase 3 | Atopic Dermatitis | Immunology | Aug 2027 |
| NCT06561321 | Tapinarof | Phase 2 | Palmoplantar Keratoderma | Immunology | Dec 2027 |
Cash of $1.5bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.